Season's Savings | ₹5/mo for 3 months

₹199/month after first 3 months. Renews automatically. Terms apply.
Altria Q3 2026 Earnings Analysis cover art

Altria Q3 2026 Earnings Analysis

Altria Q3 2026 Earnings Analysis

Listen for free

View show details
About this listen
More earnings analysis: https://betafinch.com
Groups: INCOME (https://betafinch.com/groups/INCOME)
──────────
**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're digging into Altria's third quarter 2026 results, and there's a lot on the table — from a lawsuit against the FDA to a brand-new flavor lineup for nicotine pouches. I'm Alex, here with Jordan, and we're going to break it all down for you.

**JORDAN:** Before we get into it — quick reminder, Alex, you know the drill.

**ALEX:** Right, right. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

**JORDAN:** Perfect. Okay, let's get into Altria's numbers.

**ALEX:** So headline first: adjusted diluted EPS grew 4.8% in Q3, and 5.1% through the first nine months of the year. That's solid growth for a company that's often thought of as slow and steady.

**JORDAN:** And here's the thing that jumped out at me — they actually raised guidance. Full-year adjusted EPS is now expected between $5.66 and $5.74, which works out to 4.5% to 6% growth off last year's $5.42. That's up from their original range of 2.5% to 5%. So management is feeling pretty confident here.

**ALEX:** Yeah, and that confidence is coming largely from the smokeable products segment, which is still the earnings engine for Altria. Adjusted operating company income there grew 3.9% to $3.1 billion in the quarter. Margins expanded too, up to 64.5%.

**JORDAN:** What's interesting is how they're doing it. This isn't just pure pricing power — it's a "total portfolio" strategy. Marlboro's holding the premium end, but they've also got Basic gaining share in the discount segment. Basic's retail share jumped 1.8 points year-over-year as more price-pressured smokers trade down.

**ALEX:** And then there's the new kid — Marlboro Cowboy Cut. It's basically a lower-priced premium option designed to keep value-conscious Marlboro smokers in the franchise instead of losing them to discount brands entirely. It's already in about 100,000 stores, roughly 75% of cigarette volume nationally.

**JORDAN:** Smart playbook, honestly. They've done this before with Marlboro Special Select and Marlboro Black — launch at an introductory price, then gradually take pricing up over time once it's established. And it seems to be working — Marlboro's share of the premium segment hit 60%, up slightly both year-over-year and sequentially.

**ALEX:** Now let's talk about the smoke-free side of the business, because this is where things get really interesting strategically. On! nicotine pouches — shipment volume was up 13.3% in the quarter to 47.8 million cans.

**JORDAN:** But retail share only ticked up 0.1 point year-over-year, and was actually down 0.3 sequentially. That tells you this category is getting fiercely competitive. Everybody's throwing flavors and higher nicotine strengths at the wall right now.

**ALEX:** Which is exactly what Altria's subsidiary Helix is doing in response — they just rolled out on! PLUS 12-milligram nationally, and they're adding new flavors: Blueberry Mint and Mango Pineapple hit shelves this month, with Watermelon Mint coming in November.

**JORDAN:** And don't sleep on the marketing push either — they hosted something called the "on!vitational," an invite-only golf tournament in Palm Beach. It's meant to be a recurring, multiyear brand platform. Altria's clearly trying to build lifestyle equity around on!, not just compete on nicotine strength and flavor.

**ALEX:** Now, here's the part of this call I found most newsworthy — the regulatory fight. Altria's Helix and NJOY subsidiaries actually sued the FDA this quarter.

**JORDAN:** Yeah, this is a big deal. The lawsuit is asking a court to force the FDA to stick to the 180-day review timeline that Congress set for product authorizatio

This episode includes AI-generated content.
adbl_web_anon_alc_button_suppression_t1
No reviews yet